Senior Leerink analyst downgrades Bristol Myers, citing pipeline fears
A Leerink analyst is signaling new bearishness in Bristol Myers Squibb, downgrading his view of the company’s stock because of skepticism about some key upcoming catalysts. David Risinger shifted Bristol Myers' stock from outperform to ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.